Intrepid Family Office’s Roivant Sciences ROIV Stock Holding History

Intrepid Family Office’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,000	Closed	-$303K	–	44
2025 Q3	$303K	Buy	+20,000	New	+$248K	0.25%	32

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Intrepid Family Office's ROIV Position: Q4 2025 in Review

Intrepid Family Office sold out of Roivant Sciences (ROIV) in Q4 2025, closing a stake of 20,000 shares — an estimated $303K sold.

Intrepid Family Office first reported a position in ROIV in Q3 2025 and held it in 1 quarter. The position peaked at $303K in Q3 2025. 396 funds tracked by Wall St. Rank hold ROIV as of Q4 2025.

Intrepid Family Office reported no remaining Roivant Sciences position as of Q4 2025 after selling out during the quarter.
Intrepid Family Office sold 20,000 Roivant Sciences shares in Q4 2025, an estimated $303K.
Intrepid Family Office first reported a position in Roivant Sciences in Q3 2025 and held it in 1 quarter.
Intrepid Family Office's Roivant Sciences position peaked at $303K in Q3 2025.
396 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2025.

Based on Intrepid Family Office's 13F filing for Q4 2025, filed 17 Feb 2026.